Once-weekly HIV pill shines in phase 3 trials

People with HIV who switched from daily medication to an investigational once-weekly pill containing islatravir and lenacapavir remained virally suppressed on the new combination, according to the results of two phase 3 trials.The findings, presented recently at the International AIDS Conference in Rio de Janeiro and published in The New England Journal of Medicine, were “highly